Taysha Gene Therapies, Inc. (TSHA) Dividend History

Company News

• Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

  Taysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.

  GlobeNewswire Inc.
• Breaking Down Taysha Gene Therapies: 16 Analysts Share Their Views

  16 analysts have shared their evaluations of Taysha Gene Therapies (NASDAQ:TSHA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 8 0 0 0 Last 30D 0 1 0 0 0 1M Ago 3 2 0 0 0 2M Ago 1 3 0 0 0 3M Ago 4 2 0 0 0 Analysts have recently evaluated Taysha Gene Therapies and provided 12-month price targets. The average target is $6.94, accompanied by a high estimate of $9.00 and a low estimate of $5.00. Surpassing the previous average price target of $4.75, the current average has increased by 46.11%. Interpreting Analyst Ratings: A Closer Look The perception of Taysha Gene Therapies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 $7.00 Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 - Gil Blum Needham Maintains Buy $7.00 - Eun Yang Jefferies Raises Buy $8.00 $2.00 Gil Blum Needham Maintains Buy $7.00 - Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 - Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 - Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 - Gil Blum Needham Maintains Buy $7.00 - Christopher Raymond Piper Sandler Announces Overweight $9.00 - Whitney Ijem Canaccord Genuity Maintains Buy $7.00 - Geulah Livshits Chardan Capital Raises Buy $7.00 $5.00 Silvan Tuerkcan JMP Securities Maintains Market Outperform $5.00 - Kristen Kluska Cantor Fitzgerald Maintains Overweight $7.00 - Gil Blum Needham Raises Buy $7.00 $5.00 Gil Blum Needham Maintains Buy $5.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent ...Full story available on Benzinga.com

  Benzinga
• Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

  Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: SLGL
• 3 Growth Stocks That Could Go Parabolic in 2024

  These innovation-oriented companies could take flight this year.

  The Motley Fool

  Featured Companies: ABCL CERS
• Which Penny Stocks Are Best? 3 That Insiders Like In November

  Insiders are buying these penny stocks in November. Are they on your watch list? The post Which Penny Stocks Are Best? 3 That Insiders Like In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: HRTX ONDS